ArticleFrontiers in oncology2026
Machine-learning prediction of 3- and 5-year mortality in lymph-node-positive medullary thyroid carcinoma: a study based on the SEER database and external validation in a Chinese cohort.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Medullary thyroid carcinoma (MTC) carries a disproportionately high mortality among thyroid malignancies, and the risk is even greater once metastasis occurs; nevertheless, a dependable prognostic tool for lymph-node-positive MTC patients remains elusive. We aimed to derive and externally validate a machine learning model for predicting 3-year and 5-year overall survival (OS) and cancer-specific survival (CSS) in this high-risk population. Methods: Retrospective cohorts were assembled from the U.S. SEER database (n = 1,071) and Zibo Municipal Hospital (external validation, n = 198). After feature selection (Cox, Boruta, RFE), five algorithms (LightGBM, XGBoost, RF, MLP, KNN) were trained in 70% SEER data and tested in the remaining 30% and in the Chinese cohort. F1-score, MCC, sensitivity, specificity, AUC, calibration curve, and decision-curve analysis were evaluated; model explainability was assessed with SHAP. Results: In OS prediction, LightGBM achieved the highest AUC in both time horizons (SEER 3-year 0.833, 5-year 0.892; external 5-year 0.869), with superior accuracy. Calibration curves lay closest to the 45° diagonal, and decision-curve analysis demonstrated the greatest net benefit across clinically relevant risk thresholds. SHAP revealed the absence of surgery as the strongest adverse contributor for OS, followed by advanced age, larger tumour size, higher LNR, radiotherapy and chemotherapy demonstrated adverse effects. The same pattern emerges when predicting CSS. Based on these results, we developed an online calculator for predicting 3- and 5-year OS and CSS in patients with lymph-node-positive MTC. Conclusion: LightGBM model provides an accurate, well-calibrated, and clinically useful tool for estimating survival in lymph-node-positive MTC. In addition, the decision to undergo surgery is considered the most important factor in the survival of MTC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.